Tiziana Life Sciences Share Discussion Threads

[jpuff] 17/3/2023 11:29

Tiziana Life Sciences Highlighted in Forbes Article

[michelle74] 08/3/2023 18:26

Let's hope so

[jpuff] 08/3/2023 18:15

Yes indeed. It's been painful for all holders but there are glimmers of hope I think

[michelle74] 08/3/2023 16:15

Some good news then

[jpuff] 08/3/2023 14:49

Tiziana Life SciencesPress ReleaseTiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal ForalumabMarch 8, 2023 at 7:00 AM ESTIllustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cellsFurther, highlights how intranasal foralumab has similar immune gene expression effects in COVID patients, MS patients and in heathy volunteersConcludes that immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseasesNEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab. A copy of the article can be found at pnas.org.2Howard L. Weiner, M.D., Co-Director of the Ann Romney Center for Neurologic Diseases at BWH and Chairman of Tiziana's Scientific Advisory Board, stated, "I am proud to be senior author on this important publication. The identification of a unique mechanism associated with nasal foralumab in humans was consistent across patients with COVID, multiple sclerosis and in healthy volunteers. This modulation of T cell inflammatory response that resulted from suppressing effector features in multiple T cell subsets is consistent with other research done at the Ann Romney Center and validates our scientific rationale for the upcoming IND filing to investigate intranasal foralumab in Alzheimer's."Dr. Tanuja Chitnis, M.D., Professor of Neurology at Brigham Women's Hospital (BWH) said, "It is an honor to be an author on this seminal research. Furthermore, the unique immunomodulatory signature of intranasal foralumab makes it a promising therapeutic candidate for several rare Orphan pediatric neuroinflammatory diseases, which currently remain untreated. It is my hope to study intranasal foralumab in these underserved indications.""This upcoming quarter will be an eventful and productive period for Tiziana," stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. "The publication of foralumab's detailed mechanism of action dovetails with our forthcoming Alzheimer's IND filing for intranasal foralumab and the Phase 2 FDA review comments for our proposed MS trial, all of which are expected this month. March will also be the third month of intranasal foralumab administration in four Expanded Access (EA 3 through EA 6) patients followed by data updates in Q2 2023.Tiziana remains on track to begin its Phase 2 intranasal foralumab non-active Secondary Progressive Multiple Sclerosis trial in Q3 of this year.""I am thrilled that PNAS has chosen to publish this critical research on intranasal foralumab," commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana. "Having an intranasal fully human monoclonal antibody that positively modulates the immune system allows Tiziana to explore multiple inflammatory disease indications in addition to multiple sclerosis (MS), and greatly increases the value of our groundbreaking research. The Company also notes Dr. Chitnis's exciting desire to study intranasal foralumab in rare Orphan pediatric diseases. Tiziana may pursue this unique and attractive opportunity when funding becomes available."About ForalumabActivated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.2About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.For further inquiries:Tiziana Life Sciences LtdPaul Spencer, Business Development and Investor Relations [phone]:Irina KofflerLifeSci Advisors, [e-mail] ___________________________1 https://www.pnas.org/about/article-journal-metrics2 https://www.pnas.org/doi/10.1073/pnas.2220272120 Primary LogoSource: Tiziana Life Sciences Ltd. Tiziana Life Sciences Corporate LinksAbout UsTherapeutic FocusNews & EventsInvestorsCareersContact UsSHAREHOLDER TOOLS SOCIAL LINKS Tiziana Life Sciences LTD,[e-mail] | [phone]Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. We are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales© 2023 Tiziana Life Sciences Footer Links Legal Privacy Policy

[jpuff] 08/3/2023 14:45

March 8, 2023 7:00 AM ESTTiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

[michelle74] 02/3/2023 07:33

Is anything new happening here ?

[marcus80] 21/2/2023 18:23

sure i am short AND BANKING!! easiest short out there.

[jpuff] 09/2/2023 11:45

You're a cheerful chap going round beating the doom and gloom message on many Pharma stocks. Must be short?

[marcus80] 06/2/2023 06:23

Reverse split or OTC beteren now and 3 months! Current holders can say goodbye !

[jpuff] 02/2/2023 19:50

I don't think a quick exit would be needed if they don't make a dollar. Let's see.

[michelle74] 02/2/2023 17:13

Is this good news today or are they just buying time

[lean5gb] 02/2/2023 12:48

That's the 50% I was refferring to. If they manage to reach the elusive dollar, then, happy days. If not, then a quick exit needed.

[jpuff] 01/2/2023 20:53

I'm still holding and hoping. The medical results look promising. One issue is possible delisting from Nasdaq as the stock is still well under a dollar. Obviously done news or progress could change that quickly. If delisting from Nasdaq does happen I'm not sure what the implications would be?

[lean5gb] 13/1/2023 09:34

Would this possibly be a timeful entry into tlsa, as one could benefit a 50%+ profit within a twelve week timescale?.DYOR

[david gruen] 11/1/2023 05:49

Before foralumab treatment, EA2's non-active SPMS disability had progressed, and EDSS worsened from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy that was discontinued in 2021.

In September 2022, 8 months after starting treatment with nasal foralumab, EA2 could walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2's pyramidal score remained stable during this time. In December 2022, 11 months after starting treatment with intranasal foralumab, EA2 could walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to 5.0. EA2's pyramidal score continued to remain stable.

[marcus80] 24/11/2022 06:14

“ the auditor for Tiziana Life Sciences Ltd. (the “Company”;) resigned as auditor because in its opinion the Company no longer meets their acceptable risk criteria as, in its opinion, material weaknesses in controls over financial reporting had not been sufficiently remediated.”

[abbynat] 22/11/2022 20:22

i think these are traded on their otc mkt.
correct me if i am wrong!
still waiting for the annual spike!

[lean5gb] 19/11/2022 21:40

Well,the bad news is, one of the earliest signs of cognitive impairment is the inability to finish sentences.
The good news Is

[michelle74] 16/11/2022 11:05

Just need some good news

[stenick] 15/11/2022 17:00

Cheer up it ain’t all bad

[jpuff] 27/10/2022 18:29

I wonder if it'll get kicked off the Nasdaq as below a dollar a share for quite a while now. Maybe that would be the prelude to him taking it private? I'm a holder so hope that doesn't happen but the current market is grim

[jpuff] 11/10/2022 18:19

But at a considerably lower price